DIURIL INJ Rx
Generic Name and Formulations:
Chlorothiazide (as sodium) 500mg/vial; pwd for IV inj after reconstitution; contains mannitol.
Indications for DIURIL INJ:
0.5–1g IV once or twice daily.
Anuria. Sulfonamide allergy.
Renal or hepatic impairment. Arrhythmias. Diabetes. Gout. Asthma. SLE. Postsympathectomy. Excessive fluid loss. Monitor electrolytes, BUN (if high). Potassium supplements or K+ -sparing diuretics may be needed. Discontinue if electrolyte disorders develop rapidly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Digitalis, lithium toxicity. Adjust antidiabetic, antigout medications. Antagonized by NSAIDs. ACTH, corticosteroids, amphotericin B increase hypokalemia risk. Hyperglycemia, hyperuricemia more likely with diazoxide. NSAIDs may cause renal failure. May potentiate nondepolarizing muscle relaxants, other antihypertensives. Hypotension with CNS depressants. May interfere with parathyroid tests.
Electrolyte disorders (especially hypokalemia), hyperglycemia, hyperuricemia, photosensitivity, orthostatic hypotension, GI disturbances, adverse lipid values.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC